835 related articles for article (PubMed ID: 26938559)
1. Botulinum toxin A for the Treatment of Overactive Bladder.
Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie J; Wilson DI; Herbison GP; Wilson D
Cochrane Database Syst Rev; 2007 Jul; (3):CD005493. PubMed ID: 17636801
[TBL] [Abstract][Full Text] [Related]
3. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
4. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
Ellsworth P; Travis M
Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin treatment for bladder dysfunction.
Santos-Silva A; da Silva CM; Cruz F
Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
[TBL] [Abstract][Full Text] [Related]
6. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A for the treatment of lower urinary tract disorders.
Yokoyama T; Chancellor MB; Oguma K; Yamamoto Y; Suzuki T; Kumon H; Nagai A
Int J Urol; 2012 Mar; 19(3):202-15. PubMed ID: 22220916
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Lin YH; Chiang BJ; Liao CH
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).
Tincello DG; Kenyon S; Abrams KR; Mayne C; Toozs-Hobson P; Taylor D; Slack M
Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
12. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
[TBL] [Abstract][Full Text] [Related]
13. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
15. Submucosal injections of botulinum toxin A in women with refractory idiopathic detrusor overactivity.
Onyeka BA; Shetty A; Ilangovan K; Saxena A
Int J Gynaecol Obstet; 2010 Jul; 110(1):68-9. PubMed ID: 20347085
[No Abstract] [Full Text] [Related]
16. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder.
Flynn MK; Amundsen CL; Perevich M; Liu F; Webster GD
J Urol; 2009 Jun; 181(6):2608-15. PubMed ID: 19375091
[TBL] [Abstract][Full Text] [Related]
17. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
[TBL] [Abstract][Full Text] [Related]
18. Effect of botulinum neurotoxin on the urinary bladder: novel insights on mechanism of action.
Vianello A; Proietti S; Giannantoni A
Minerva Urol Nefrol; 2010 Sep; 62(3):259-71. PubMed ID: 20940695
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity.
Kuo HC
J Urol; 2007 Oct; 178(4 Pt 1):1359-63. PubMed ID: 17706718
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
